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Bayesian decision theory describes a decision making problem through a set of feasible alternatives, a 2A; a set of states
or parameters, h 2 H; a prior distribution, pðhÞ; a likelihood, lðxjhÞ; and a utility function, uða; h; xÞ. Usually, the utility function
does not depend on the data x. In such cases, we write uða; hÞ.
The optimal decision a is the alternative that maximizes the posterior expected utility:a ¼ arg max
a2A
UðaÞ; ð1Þ
UðaÞ ¼
Z
H
uða; h; xÞpðhjxÞdh ¼
R
H uða; h; xÞlðxjhÞpðhÞdhR
H lðxjhÞpðhÞdh
: ð2ÞIn some cases, the interest focuses on ﬁnding an optimal decision before observing data, changing (2) to:UðaÞ ¼
Z
H
uða; hÞpðhÞdh:Among many reviews of Bayesian decision theory see, for example, [1–3].
Practical implementation of (1) is hindered by the fact that UðaÞ and, hence, the optimal action a could be sensitive to the
chosen prior pðÞ, likelihood lðjÞ and/or utility function uðÞ. A skeptical decision maker will require, in addition to the opti-
mal solution, some description of its robustness with respect to reasonable changes and imprecisions in the speciﬁcation of
inputs. Moreover, the resolution of (1) must frequently be performed by simulation-based methods, mainly by Markov chain
Monte Carlo (MCMC) ones. In these cases, robust analyses may become very involved computationally.. All rights reserved.
arper@unex.es (C.J. Pérez), pm@odin.mdacc.tmc.edu (P. Müller).
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to the prior and the likelihood is studied in [8,9]. Sensitivity with respect to the loss function is considered in [10,11]. Joint
sensitivity with respect to the utility function and the prior is investigated in [12]. Discussions concerning applications to
medical models, as the ones we shall pursue here, may be found in [7,13,14].
In this paper, we address the robustness of the optimal action in a decision making problem with respect to the prior
model or the utility function. We discuss several general principles and apply new computational strategies in the context
of two relatively complex medical decision making problems. The outline of the paper is as follows. In Section 2, we discuss
some general principles and new computational strategies to address a robust analysis with respect to the prior distribution
or the utility function. Some theoretical results are provided. In Section 3, the proposed robustness analysis is applied to two
medical decision making problems, that are representative of a wide range of applications in that area. Section 4 provides
conclusions. An Appendix includes proofs of the theoretical results. We emphasize that the developed methodology is poten-
tially applicable to many decision making problems and not just to those described through this paper.2. Bayesian robustness approach
In this section, UðaÞ is represented as Uða;u; pÞ because of the dependence relationship. Two key sensitivity aspects (see,
for example, [15]) in a decision making problem are:
1. Expected utility sensitivity. Changes in the expected utility of a as a function of ðu; pÞ. It should be, therefore, undertaken a
study of the operator:ðu; pÞ ! Uða;u; pÞ: ð3Þ
2. Decision sensitivity. Changes in the optimal decision a if we modify ðu; pÞ. Let b be an alternative solution to a: If for some
ðu; pÞ within a reasonable range of the original assessment, Uða;u; pÞ  Uðb;u; pÞ < 0; then, action b is preferred to the
incumbent optimal action a. The operators of interest include:ðu; pÞ ! Uða;u; pÞ  Uðb;u; pÞ; ð4Þwhich expresses differences in expected utility between a and b when ðu; pÞ changes;ðu; pÞ ! argmax
a
Uða;u; pÞ; ð5Þwhich expresses how the optimal alternative changes as ðu; pÞ changes, and
ðu; pÞ ! Uða;u; pÞ max
b2A
Uðb;u; pÞ; ð6Þwhich expresses maximum differences in expected utility between a and the set of alternatives b 2A, as ðu; pÞ changes.
When the value of this operator is 0, a remains optimal for any ðu; pÞ.
In this paper, we focus on sensitivity with respect to the prior distribution, by considering the operator given in (3), and
the operators given by (4) and (5) when the utility function changes.
2.1. Sensitivity with respect to the prior distribution
Many papers on Bayesian robustness have studied this question only focusing on changes in the prior distribution p,
allowing p to range in various classes C of probability distributions. See, for example, [4,5,16,17] and references therein.
In order to quantify local sensitivity with respect to prior changes, [18] proposed to consider the derivative _Up of U with
respect to p (given a and u), deﬁned as the linear operator such that:Uða;u; pþ hÞ ¼ Uða;u; pÞ þ _UpðhÞ þ oðkhkÞ as khk ! 0;
where h is a 0 mass signed measure, and khk is the bounded variation norm:khk ¼ sup
B2B
jhðBÞj:When the decision problem does not include data to update the prior distribution, then _UpðÞ ¼ UðÞ because UðÞ is linear in
p. Wemay think of _UpðhÞ as a rate of change of the expected utility if we change the prior probability measure from p to pþ h.
The use of such derivatives in robust Bayesian analysis is reported, among others, in [19–22].
Here, we consider changes in expected utility when varying the prior p. Hence, in the following discussion, the decision a
and the utility u are ﬁxed, and we denote UðpÞ ¼ Uða;u; pÞ. The practical impact of the computed prior sensitivity measure
would be the following: large values suggest the decision maker that any conclusion should not be applicable to values ðu; pÞ
far apart from the initial ones. A more careful prior elicitation might be in order. On the other hand, low values imply that the
conclusions can be considered reasonably robust against changes in the prior probability.
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a particular prior probability model p 2 C; we study the impact of changes in p on the expected utility of a. We use neigh-
borhoods Ce#C of p deﬁned via e-contaminations, i.e.:Ce ¼ fp0 ¼ pþ gðq pÞ; q 2 C; 0 6 g 6 eg:These neighborhoods are commonly used in sensitivity analysis, see, e.g., [1,4,7,11].
For a given p and a given neighborhood Ce of alternative prior models p0 around p, the following sensitivity measure is
deﬁned in [21]:mep ¼ sup
p02Ce
j _Upðp0  pÞj:Note that this supremum is an upper bound on the changes in expected utility when varying the prior model inﬁnitesimally
in this class asjUðp0Þ  UðpÞj 6 sup
q2Ce
j _Upðq pÞj þ ðkp0  pkÞ;where _Up is the derivative of U with respect to p evaluated at d ¼ p0  p. Due to the fact that kp0  pk 6 e 8p0 2 Ce, we deﬁne
an inﬁnitesimal sensitivity measure for the prior distribution p asmp ¼ lim
e!0
mep
e
:With this deﬁnition, we remove dependence on e. Therefore, this quantity measures the maximum variation.
The remaining problem is how to evaluate that supremum. For the following quantile class CQ of probability measures
and the e-contamination neighborhood Ce#CQ , Theorem 1 provides an algorithm to compute the supremum through the
solution of linear programming problems. The quantile class is given byCQ ¼ fr : pj 6 rðAjÞ 6 pj; j ¼ 1; . . . ;ng;
where A1; . . . ;An is a measurable partition of H with
Pn
j¼1pj 6 1 6
Pn
j¼1pj. The e-contamination neighborhood Ce#CQ isCe ¼ fp0 ¼ pþ gðq pÞ; q 2 CQ ; 0 6 g 6 eg:Theorem 1. When the probability model does not include data, given p 2 CQ and Ce#CQ , then:
mep ¼ sup
p02Ce
j _Upðp0  pÞj ¼maxfH1  UðpÞ;UðpÞ  H2ge;where H1 and H2 are, respectively, the optimal values of the linear programming problems:max
Pn
j¼1
pjhj; min
Pn
j¼1
pjhj;
s:t:
Pn
j¼1
pj ¼ 1; s:t:
Pn
j¼1
pj ¼ 1;
pj 6 pj 6 pj; j ¼ 1; . . . ;n; pj 6 pj 6 pj; j ¼ 1; . . . ;n;
with hj ¼ suph2Ajuða; hÞ and hj ¼ infh2Ajuða; hÞ.
When the probability model contains data, the prior distribution may be updated by Bayes’ theorem. In this case, we may
compute the derivative by using a result in [18] and the supremum of the derivative can be calculated as in [21]. Concretely,
the calculations can be performed by using Theorems 1 and 3 in [11,21].
2.2. Sensitivity with respect to the utility function
We now study changes in Uða;u; pÞ  Uðb;u; pÞ as we vary the utility function and the alternative b, i.e., the operators in
(4)-(6) are analyzed when both the incumbent optimal decision and the utility change. We focus on a class of utility func-
tions which are typical for a wide range of medical applications, as it is shown in the next section. They include a trade-off
between a term related to sampling cost and a term referring to the posterior (predictive) probability of some event of inter-
est, that we aim at detecting. Interesting issues for Bayesian robustness concerning other utility functions can be found in
[23].
Speciﬁcally, assume that the class of utility functions U is composed by functions of the type:uða; hÞ ¼ rna  1Eða; hÞ;
where na 2 N is the number of samples under action a, E is an objective event, 1E is the indicator function for E and r is the
ratio between sampling cost and the penalty of underachieving the objective. Then, the expected utility is of the form
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where f ðaÞ is the probability of achieving the objective. In Section 3 we illustrate the values with examples.
We study now the impact of the ratio r in the variation of the optimal alternative, through operators (4)–(6). The ﬁrst
result is immediate.
Proposition 1. The utility functions belonging to U, where r > 0, verify:
(a) If a is the optimal decision for the initial r, then 8s > 0, UsðbÞ 6 UsðaÞ 8b such that nb ¼ na .
(b) If a is the optimal decision for the initial r, then 8s > r, UsðbÞ < UsðaÞ 8b such that nb > na .
(c) If a is the optimal decision for the initial r, then 8s < r, UsðbÞ < UsðaÞ 8b such that nb < na .
Therefore, in order to ﬁnd out how much r may decrease without changing the optimal decision, we have to consider deci-
sions d such that na ¼ na þ k ðkP 1Þ. Then, the following result is obtained.
Theorem 2. The parameter r may be decreased as much as Dr without changing the optimal solution, whereDr ¼ r þmin
kP1
min
b2Dk
f ðbÞ  f ðaÞ
k
0
@
1
Aand Dk ¼ fa : na ¼ na þ kg.
Similarly, we consider decisions a;with na ¼ na  k, ðkP 1Þ, to know how much r can be increased without changing the
optimal decision. Then, a result analogous to Theorem 2 is:
Theorem 3. The parameter r may be increased as much as Dr without changing the optimal solution, whereDr ¼min
kP1
min
b2D0k
f ðbÞ  f ðaÞ
k
0
B@
1
CA rand D0k ¼ fa : na ¼ na  kg.
Through this section, we have discussed some general principles and proposed new computational strategies, which we
will illustrate with two relatively complex medical decision making problems in the next section. Note that we are using
operators (5) and (6), looking for changes in the optimal decision. Moreover, Proposition 1 can be applied to study operator
(4).
3. Applications to medical decision making
We use two medical decision making examples which are typical for a wide range of applications in this area. The exam-
ple in Section 3.1 is typical for applications verifying: (i) a semi-Markov model describing transitions between different
stages of a disease; (ii) the utility function combines a sampling cost and a payoff related to some event that is easy to eval-
uate for any assumed values of future data y and parameters h. The example in Section 3.2 has some key features of another
wide class of problems in medical decision making: (i) a parametric hierarchical model to ﬁt data from previous patients is
used; (ii) the model is estimated through MCMC posterior simulation; (iii) the expected utility of any alternative contains
one term related to sampling cost and another term related to the posterior (predictive) probability of some event of interest.
Other important examples of medical decision making problems with similar features include optimal scheduling of
chronic diseases ([24–29]) and optimal design for implantable heart deﬁbrillators ([30–32]).
3.1. Optimal screening schedules for breast cancer
The problem of optimal screening schedules for a chronic disease as, for example, breast cancer is considered in [27]. The
decisions to be made include the age a at which to begin regular screening and the frequency d of screenings, i.e., a ¼ ða; dÞ. A
four state semi-Markov process to describe the history of a chronic disease is deﬁned in [27,28,33]. The four states are ‘‘dis-
ease is absent or present but not detectable” (A), ‘‘detectable pre-clinical” (B), ‘‘clinical” (C) and ‘‘death”(D).
For breast cancer, the following speciﬁcations are used in [27]. Let p denote the transition probability from A to B (1  p is
the transition probability from A to D), t2 is the transition time from A to B, t3 is the transition time from B to C, and t4 is the
transition time from A to D. Also, t1 ¼ 1 or t1 ¼ 0 shows whether a patient’s state changes from A to B or from A to D. We
denote with h ¼ ðt1; t2; t3; t4Þ the patients history. For the sake of simplicity, we assume no transitions between B and D are
possible. If not detected, every pre-clinical case develops into a clinical case in t3 years. Let f^ 2ðt2Þ denote the empirical dis-
tribution for t2 based on historical data, and let y be a patient’s age, when entering state B. In [27], it is proposed to use
p ¼ 1=8 and
Table 1
Probabi
pi
t2 2 ð0;
t2 2 ð20
t2 2 ð30
t2 2 ð40
t2 2 ð60
t2 2 ð80
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t4 Weibullða4; b4Þ;
logðt3Þ  Nðmt2 ; s2Þ;
s2  Gammaða3; b3Þ;with a4 ¼ 7:233, b4 ¼ 82:651, a3 ¼ 6:33, b3 ¼ 3:36, m0 ¼ 1:4, m1 ¼ 1:6, m2 ¼ 0:038, and mt2 ¼ m0  expðm1 þm2t2Þ. Fig. 1
shows the probability model.
Deciding on an optimal screening schedule requires specifying in the utility function the trade-off r between the screen-
ing cost and the probability of early breast cancer detection. Let E denote this event. Let naðhÞ be the number of screenings
under the state h and the schedule a. The utility function is given byuða; hÞ ¼ rnaðhÞ þ 1Eða; hÞ; ð7Þ
where 1Eða; hÞ is 1 if, for h, we detect breast cancer early, and 0 otherwise.
For a trade-off parameter r ¼ 0:001, the maximal expected utility is achieved at a ¼ 42, d ¼ 1:96, with value 51.8202.
Note that the expected utility value has been scaled by a factor of 1000 in order to avoid numbers of low order of magnitude.
We consider uncertainty in the probability model for t2 and t3. By using the previous information, and for illustration pur-
pose, we embed the prior distribution into a quantile class with two classes for t3 and six classes for t2. We then obtain 12
classes, as shown in Table 1, where for example Pðt2 2 ð40;60; t3 2 ½0;1:96Þ ¼ 0:19654, for the basic assessment. Note that
t2 and t3 are not independent. We deﬁne the quantile class CQ ; and the corresponding family Ce; by matching the quantiles
given in Table 1, i.e., lower and upper bound in the general deﬁnition of CQ are tied.
We compute hj and hj for each element in the partition. We obtain H1 ¼
P12
j¼1pj
hj ¼ 96:2194 and H2 ¼
P12
j¼1pjhj ¼ 25:1675.
Moreover, UðpÞ ¼ 51:8202. By applying Theorem 1, we obtain:
mep ¼ sup
p02Ce
j _Upðp0  pÞj ¼maxf96:2194 51:8202;51:8202 25:1675ge ¼ 44:3992 e;and, therefore, mp ¼ 44:3992: We might conclude that there is no robustness in expected utility, since the value mp is large
when compared with the value of UðpÞ. This lack of robustness conﬁrms the discussion on optimal screening designs for
breastcancer. The expected utility surface is extremely ﬂat in a relatively wide neighborhood of the optimal solution, leaving
opportunity for extensive disagreement with the optimal schedule. To further understand the nature of this lack of robust-
ness, we consider a reduced quantile class deﬁned by reﬁning the partition.
In this case:mp ¼ H1  UðpÞ ¼
X12
j¼1
pjhj  UðpÞ ¼ 44:3992:After observing the values pjhj, it is deduced that the most inﬂuential variable is t3. Then, we split the intervals for t3, as in
[34], becoming now (0,1.80], (1.80,1.96], (1.96,4], and (4,80.18]. New probabilities are assigned for the subintervals, and
then, the new value of mp is 26:3005, which is a considerable reduction. The process can be repeated to obtain more reduc-
tion in the sensitivity measure by using the expert opinion information.lities pi of the partition for the prior distribution
t3 2 ½0;1:96 t3 2 ð1:96;80:18
20 0.00643 0.00040
;30 0.02603 0.00241
;40 0.06070 0.01447
;60 0.19654 0.19895
;80 0.13023 0.27854
;105 0.02130 0.06400
t ~f (t ) t ~f (t |t ,a ,b ,m ,m ,m )
t ~f (t |a ,b )
CBA
D
1/8
7/8
Fig. 1. Probability model for transitions among the four states.
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Optimal apheresis designs for cancer patients undergoing high-dose chemotherapy is considered in [35]. Between a pre-
treatment and the start of chemotherapy, stem cells are collected to allow for later reconstitution of white blood cell com-
ponents. There are two possible treatments. Depending on which one the patient undergoes, the ﬁrst stem cell collection
process (apheresis) is scheduled on the ﬁfth or seventh day after pre-treatment. The problem is to decide for which of
the remaining days further aphereses should be scheduled. Clearly, the optimal solution should propose stem cell collections
on days with high predicted stem cell concentrations. The prediction is based on observations of stem cell levels (represented
by CD34 antigen levels) from past patients.
Let yij, i ¼ 1; . . . ; I and j ¼ 1; . . . ;ni denote the observed CD34 count for patient i on day tij. Let yi ¼ ðyi1; . . . ; yini Þ and
y ¼ ðy1; . . . ; yIÞ denote the ith patient’s data and the combined data vector. A sampling model for the data is speciﬁed in
[35]. For a new patient, h ¼ I þ 1, let yh ¼ ðyh1; . . . ; yhnh Þ be the (unknown) stem cell counts on days th1; . . . ; thnh . Denote with
a ¼ ðd1; . . . ; dnh Þ a vector of indicators, with dj ¼ 1ð0Þ if a stem cell collection is (not) scheduled for day thj. For the ﬁrst day th1,
there is a count, yh1, already available. Let na ¼ 1þ
Pnh
j¼2dj denote the number of scheduled apheresis, where the ﬁrst 1 re-
ﬂects the apheresis at day th1 already realized. Let A be the event of failing to collect a target number y of stem cells, i.e.,
A ¼ fPnhj¼1djyhjLh < yg, where Lh is the volume of blood processed at each stem cell collection for the new patient (yij is re-
corded per volume unit). The utility function isuða; yhÞ ¼ c1na  c21Aða; yhÞ; ð8Þwhere 1A is the indicator function for event A, c1 is the cost of each apheresis, c2 is the penalty for under-achievement of the
target y and na is the number of apheresis under alternative a. The decision making problem is then:a ¼ argmax
a
Z
H
uða; yhÞpðyhjhÞpðhjyÞdh; ð9Þwhere pðhjyÞ / lðyjhÞpðhÞ is the posterior distribution on the unknown model parameters given the observed data y.
In [35], (9) is solved for a particular model pðyjhÞ based on a rescaled Gamma curve for the mean proﬁle of each patient
and a hierarchical prior probability model. A covariate, xi ¼ 1 or xi ¼ 2, records each patient’s pre-treatment. The two pre-
treatments deﬁne the choice of the prior distribution at the ﬁrst level. The hyperprior at the second level is common for both
pre-treatments. The model is given byyij ¼ zigðtij; ei; siÞ þ ij; i ¼ 1; . . . ; I; j ¼ 1; . . . ;ni;
ij  Nð0; r2Þ;
hi  Nðgxi ;VÞ;
hi ¼ ðzi; ei; siÞ;
gxi  Nðl;RÞ;
V1 Wishartðq; ðqQÞ1Þ;
r2  Gammaða0=2; b0=2Þ:
ð10ÞHere gðt; e; sÞ ¼ Cðt; a; bÞ=c is the density function of a Gamma distribution with parameters b ¼ e=s2 and a ¼ e  b, chosen to
have mean and variance matching e and s2 and rescaled by c ¼ ½ða 1Þ=ba1 exp½ða 1Þ such that supðgÞ ¼ 1. The rescaling
factor is zi. See Fig. 2 for a schematic representation of model (10).
By using MCMC posterior simulation, the optimal design a for a future patient in model (10) with respect to the utility
function (8) with c1=c2 ¼ 0:1 can be found. As an example, for a patient undergoing pre-treatment 1, the optimal apheresis
schedule was found to be a ¼ ð1;1;0;0;0;0;0Þ, with expected utility UðaÞ ¼ 2:03.
We consider patients 24 and 25 and apply the results in Section 2.2. Patient 24 begins the stem cell collection on the ﬁfth
day after pre-treatment with Lh ¼ 20 and y ¼ 200: For patient 25, stem cell collection begins on the seventh day after the
pre-treatment. Again, in this case we have the same values for Lh and y. Tables 2 and 3 summarize the best ﬁve solutions for
patients 24 and 25, respectively.
By using Theorem 2 for patient 24, we obtain Dr ¼ 0:09795: The current value of r is 0.1, then we can decrease r by 97.95%
without changes in the optimal alternative. If we take r ¼ 0:1 0:09795, we ﬁnd that alternatives a4 and a5 become optimal.
Note that in the original utility function we used c1 ¼ 1 and c2 ¼ 10 instead of r, with r ¼ c1=c2. In this case, c2 could increase
from 10 to 490 without changes in the optimal solution. On the other hand, applying Theorem 3, we ﬁnd that r could increase
by 0.4040816 (404.08%) without changes in the optimal solution. For values of r greater than 0.5040817, the optimal solution
indicates stem cell collection only on the ﬁfth day. We conclude that the solution is fairly robust for changes in the utility
function for patient 24.
We repeat the study for patient 25, obtaining different results. The parameter r can decrease only by 4.08% without
changing the optimal solution. Then, alternative a2 becomes optimal. However, r could be increased by 165%. In this case,
the optimal alternative is to collect stem cells on days seventh and ninth, with expected utility equal to 8.91. This alterna-
tive is not among the best ﬁve ones. The key conclusion is that the optimal solution is robust against increasing changes and
sensitive for decreasing changes.
Table 2
Top ﬁve solutions for patient 24
Decision Days to collect UðÞ
a1 5th and 6th 2.03
a2 5th and 7th 2.08
a3 5th and 8th 2.59
a4 5th, 6th and 7th 3
a5 5th, 6th and 8th 3
, 0 0,
1 V
y1 j
1
y2 j
2
y
I
1
z e s1 1 1 z e s2 2 2 z e sI I I
hyperparameters
2
n daysI
…
…
Fig. 2. Graphical model (10). Rectangular boxes correspond to ﬁxed hyperparameters. Rounded boxes are unknown parameters. Circles are observable data.
Arrows show conditional dependence.
Table 3
Top ﬁve solutions for patient 25
Decision Days to collect UðÞ
a1 7th, 9th and 10th 5.102
a2 7th, 9th, 10th and 11th 5.143
a3 7th, 10th and 11th 5.224
a4 7th, 9th, 10th and 12th 5.429
a5 7th, 9th, 11th and 12th 5.429
J. Martín et al. / International Journal of Approximate Reasoning 50 (2009) 315–323 321The practical implication is that the one could comfortably recommend collection on days 5th and 6th, and on days 7th,
9th and 10th, respectively for patients 24 and 25. Also a clinician might choose for additional collection on day 11th, if de-
sired, for patient 25. Although the recommendation is based on a formal decision theoretical setup, with a speciﬁc probabil-
ity model and loss function, the conclusion is more general. One particular feature that traditionally prevents many
researchers from applying formal decision theoretical approaches in biomedical problems is the need for a speciﬁc utility
(or loss function). It is often not clear who is the relevant decision maker and whose loss function should be used, how should
monetary costs and health beneﬁts be traded off, etc. The proposed study of robustness and sensitivity mitigates some of
these concerns and can facilitate increased use of decision theoretical methods in biomedical applications.
Finally, note that the same MCMC outputs obtained to approximate the optimal design have been used in the sensitivity
analysis. This type of analysis has a low computational cost (see, for example, [36]).
4. Conclusion
The Bayesian approach provides a coherent methodology for decision making under uncertainty. In this context, robust
analysis should be incorporated to ﬁnd out how the output of the model changes with variations in the inputs. In this paper,
we have discussed some general principles referring to some of the most important works in the ﬁeld of Bayesian robustness.
322 J. Martín et al. / International Journal of Approximate Reasoning 50 (2009) 315–323New computational strategies have been proposed and their applicability has been illustrated in the context of two relatively
complex medical decision making problems. The special importance of decisions in the medical context makes this kind of
analysis necessary.
When the complexity of the model increases, the sensitivity analysis becomes also more involved. For example, sensitiv-
ity analysis in MCMC methods is a difﬁcult task demanded by several authors. Particularly relevant is the fact that MCMC
simulations can be re-used to estimate the sensitivity measures of the proposed approaches avoiding the need for further
sampling.
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Appendix A. Proofs
Proof 1 (of Theorem 1). If p0 ¼ pþ gðq pÞ then:
j _Upðp0  pÞj ¼ j _Upðgðq pÞÞj ¼ jUðgðq pÞÞj ¼ gjUðqÞ  UðpÞj;therefore,mep ¼ sup
p02Ce
j _Upðp0  pÞj ¼ sup
q2CQ ;g6e
gjUðqÞ  UðpÞj ¼ e sup
q2CQ
jUðqÞ  UðpÞj ¼ emax sup
q2CQ
ðUðqÞ  UðpÞÞ; inf
q2CQ
ðUðqÞ  UðpÞÞ
( )
:We need to compute supq2CQ UðqÞ and infq2CQ UðqÞ. For the supremum, we have, for s>0:sup
q2CQ
UðqÞ ¼ sup
q2CQ
Z
H
uða; hÞqðhÞdh ¼ sup
q2CQ
Xn
j¼1
Z
Aj
uða; hÞqðhÞdh;and for all q 2 CQ ; we have, j ¼ 1;2; . . . ;nZ
Aj
uða; hÞqðhÞdh 6 qðAjÞ sup
h2Aj
uða; hÞ:Since pj 6 qðAjÞ 6 pj; then
R
H uða; hÞqðhÞdh 6 H1: Moreover, 9q 2 CQ such that UðqÞ ¼ H1. Analogously, the inﬁmum is ob-
tained. So, we have mep ¼ maxfH1  UðpÞ;UðpÞ  H2g e. h
Proof 2 (of Proposition 1). We prove (a) and (b). (c) is similar to (b).
(a) Let b be such that nb ¼ na . Since a is optimal for the initial r, we have, for s>0;r nb  f ðbÞ 6 r na  f ðaÞ ()  f ðbÞ 6 f ðaÞ ()  snb  f ðbÞ 6 sna  f ðaÞ () UsðbÞ 6 UsðaÞ
(b) Let b be such that nb > na . Then, nb can be represented as nb ¼ na þ k: If s > r then: r nb  f ðbÞ 6 r na  f ðaÞ ()  r ðna þ kÞ  f ðbÞ 6 r na  f ðaÞ ()
 r k f ðbÞ 6 f ðaÞ ()  sk f ðbÞ < f ðaÞ ()  sna  sk f ðbÞ < sna  f ðaÞ
 s ðna þ kÞ  f ðbÞ < sna  f ðaÞ
 snb  f ðbÞ < sna  f ðaÞ () UsðbÞ < UsðaÞ Proof 3 (of Theorem 2). By Proposition 1, if r decreases, a is preferred to any alternative b with nb 6 na . Let b be such that
nb ¼ na þ k. Alternative b is preferred to a with a trade-off r  Dr if and only if: ðr  DrÞðna þ kÞ  f ðbÞ > ðr  DrÞna  f ðaÞ () Dr > f ðbÞ  f ða
Þ
k
þ rAs we look for the minimum Dr, we obtain the proposed result. h
Proof 4 (of Theorem 3). Analogous to the previous proof. hReferences
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